Vivo Capital’s Galmed Pharmaceuticals GLMD Stock Holding History

Vivo Capital’s Portfolio GLMD Stock Details GLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-4,778	Closed	-$4.11M	–	66
2020 Q2	$4.11M	Hold	4,778	–	–	0.29%	49
2020 Q1	$2.98M	Buy	+4,778	New	+$4.54M	0.27%	46
2019 Q3	–	Sell	-5,396	Closed	-$7.14M	–	16
2019 Q2	$7.14M	Hold	5,396	–	–	0.67%	31
2019 Q1	$7.94M	Hold	5,396	–	–	0.79%	32
2018 Q4	$6.63M	Buy	5,396 +665	+14%	+$1.16M	0.85%	30
2018 Q3	$11.6M	Buy	4,731 +327	+7%	+$765K	1.17%	23
2018 Q2	$9.43M	Buy	+4,404	New	+$6.38M	1.22%	23

Other funds holding GLMD

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

PAWC

P.A.W. Capital Greenwich, Connecticut $128M AUM 46.78% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Vivo Capital's GLMD Position: Q3 2020 in Review

Vivo Capital sold out of Galmed Pharmaceuticals (GLMD) in Q3 2020, closing a stake of 4,778 shares — an estimated $4.11M sold.

Vivo Capital first reported a position in GLMD in Q2 2018 and held it in 7 quarters. The position peaked at $11.6M in Q3 2018. 24 funds tracked by Wall St. Rank hold GLMD as of Q3 2020.

Vivo Capital reported no remaining Galmed Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Vivo Capital sold 4,778 Galmed Pharmaceuticals shares in Q3 2020, an estimated $4.11M.
Vivo Capital first reported a position in Galmed Pharmaceuticals in Q2 2018 and held it in 7 quarters.
Vivo Capital's Galmed Pharmaceuticals position peaked at $11.6M in Q3 2018.
24 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q3 2020.

Based on Vivo Capital's 13F filing for Q3 2020, filed 13 Nov 2020.